Summary The early and late morphological changes induced in rat bladder urothelium by intravesicular administration of the alkylating agents methyl methanesulphonate (MMS) and ethyl methanesulphonate (EMS) are described. In the short-term, both compounds produced dose-related toxic damage followed by a regenerative hyperplasia of the urothelium. At any given dose-level, the effects of MMS were more severe than those of EMS. Previous experiments in this laboratory established that the alkylating agent N-methyl-N-nitrosourea (MNU) is both a powerful hyperplastic agent and a bladder carcinogen when administered by intravesicular instillation (Hicks and Wakefield, 1972) . This finding has provided a useful model system in which the mechanisms of carcinogenesis and the effects of modulators can be explored (Hicks, 1980; Hicks et al.,1975 Hicks et al., , 1978 Severs et al., 1982) . Intravesicular instillation of two other alkylating agents, viz. methyl methanesulphonate (MMS) and ethyl methanesulphonate (EMS) in the short-term produced toxic damage followed by urothelial hyperplasia (Wakefield & Hicks, 1974 
Previous experiments in this laboratory established that the alkylating agent N-methyl-N-nitrosourea (MNU) is both a powerful hyperplastic agent and a bladder carcinogen when administered by intravesicular instillation (Hicks and Wakefield, 1972) . This finding has provided a useful model system in which the mechanisms of carcinogenesis and the effects of modulators can be explored (Hicks, 1980; Hicks et al.,1975 Hicks et al., , 1978 Severs et al., 1982) . Intravesicular instillation of two other alkylating agents, viz. methyl methanesulphonate (MMS) and ethyl methanesulphonate (EMS) in the short-term produced toxic damage followed by urothelial hyperplasia (Wakefield & Hicks, 1974) .
Both EMS and MMS have been reported to induce neoplasia in mice and rats following s.c. or i.p. injection (data reviewed in IARC, 1974) . In rats, the lowest doses reported to produce tumours following a single intraperitoneal injection were 100mgkg-1 EMS and 72mgkg-1 MMS. EMS produced mainly lung and kidney tumours whereas MMS produced local tumours and tumours of the nervous system. Oral administration of MMS to mice for life was reported to increase the incidence of lung tumours and lymphomas. Although there was no indication that EMS and MMS were carcinogenic for the urinary bladder, the fact that in our previous work they were found to elicit urothelial hyperplasia warrants further investigation. The present study was therefore undertaken to determine the short-term doseresponse of the rat bladder to single doses of EMS and MMS, and to assess whether single or multiple doses of these agents have any carcinogenic potential for the urothelium in long-term trials.
Materials and methods

Chemicals
Methyl methanesulphonate (MMS) was obtained from Cambrian Chemicals Ltd., Croydon, Surrey and ethyl methanesulphonate (EMS) from Sigma London Chemical Company Ltd., Poole, Dorset. Both chemicals were used as supplied.
Animals and diet Specific-pathogen-free female Wistar rats, free from the bladder parasite, Trichosomoides crassicauda, were supplied by A. Tuck and Son Ltd. (Battlesbridge, Essex). They were caged in groups of 6 in rooms kept at 19-220C with a relative humidity of 50-60% and were maintained on Dixon's standard pelleted 41B diet and tap water ad libitum. The animals were 6-8 weeks old at the beginning of treatment and weighed 135-175g. They were observed daily for signs of ill health; those that became ill and whose condition did not improve were killed and subjected to post-mortem examination.
prior to each dosing session. Catheters were made from 4cm lengths of Portex tubing (pplO, Portex Ltd., Hythe, Kent) and sterilized in 70% ethanol. Rats were anaesthetized by i.p. veterinary nemnbutal (May and Baker Ltd., Dagenham, Essex), and a catheter inserted via the urethra into the bladder of each animal. To minimise any alteration in the concentration of MMS or EMS by dilution with urine in the bladder, micturition was induced by gentle pressure to the lower abdomen.
The MMS and EMS solutions were instilled in a volume of 0.15cm3 using a graduated syringe with a 30 G needle, which fitted into the end of the catheter. After dosing, the catheter was gently withdrawn from each bladder, and the animals returned to cages where they were kept warm during the recovery period.
Experimental design
Three experiments were carried out to investigate the short-term effects of MMS and EMS on the urothelium. In the first, rats each received a single intravesical dose of 15mg (100mgkg-1) of EMS and were killed at intervals of 2 h, 4 h, 1 day, 4 days and 7 days after treatment. In the second experiment, single doses of 3.6mg (20mgkg-1) and 8.75 (50mg kg-1) of each compound were given and the rats killed at 1 and 7 days post-dosing. Single doses of 2.4mg (15mgkg-1) MMS and 6.2mg (35mgkg-1) EMS were used in the third experiment and the animals killed at 1 and 7 days. These experiments enabled a dose of each compound to be selected which elicited a similar biological effect, namely a moderate hyperplasia with minimal toxic damage, for use in the longterm trial. On the basis of the findings (see Results section) a dose of 2.5mg was selected for MMS, and 7.5mg for EMS.
For the long-term study, rats were randomly distributed into 9 groups (A to I). Animals in group A were not treated and were maintained as the control group. Rats in groups B-E received one to four doses of 2.5mg MMS, and those in groups F-I received one to four doses of 7.5mg EMS. (See Table I for details.) The multiple doses were administered at intervals of 2 weeks.
Post-mortem procedures and tissue preparation Animals that died during the study were autopsied, unless this was precluded by ad-ianced autolysis or cannibalism. Those found in extremis or surviving to 2 years after the initial dose were killed by cervical dislocation and their bladders exposed through an abdominal incision. The urethra was clamped and the bladder gently inflated by injection of 0.5 cm3 of 10% phosphate-buffered formalin (pH 7.4) into the lumen with a fine needle introduced through the dome. Its serosal surface was bathed with the same fixative and after 4 minutes fixation in situ the bladder was dissected free.
After removal, the bladder was cut longitudinally into two halves and examined under a dissecting microscope for gross lesions (e.g. thickened areas, tumours and calculi). In bladders of normal macroscopic appearance, one half was further fixed in 10% formalin prior to processing and embedding in paraffin wax. Sections of 4 gm were cut and stained with haematoxylin and eosin. The other half was cut into 1 mm3 blocks and post-fixed in cold 0.1 M cacodylate-buffered 1% osmium tetroxide. After dehydration at room temperature in graded concentrations of alcohols, the tissue was embedded in Spurr resin. Semi-thin (1 pm) sections were cut and stained with toluidine blue for high resolution light microscopy. At least three blocks from each bladder were examined by this method to complement the results obtained by conventional histology.
In tumour-bearing bladders, areas of each tumour and of the bladder wall were prepared for both wax and resin embedding. Bladders from animals that were found dead were processed for wax-embedding only.
Results
Classification of urothelial lesions
The typical appearance of normal urothelium from an untreated control animal is shown in Figure la . For assessment of both short-term and long-term effects of MMS and EMS, urothelial hyperplasia was defined as urothelium more than 3 cell layers thick. Simple hyperplasias were further sub-divided into mild, moderate and marked categories. Mild hyperplasia was defined as areas 4-6 cell layers thick (Figure lb) , moderate hyperplasia as areas 7-10 cells thick ( Figure lc ) and marked hyperplasia as areas > 10 cell layers thick ( Figure Id) . It was also noted whether the lesions were focal or diffuse in nature, the lesions being regarded as diffuse only when >20% of the epithelium was hyperplastic. Nodular and papillary hyperplasias were recorded as a separate category. For each bladder, the grade of lesion recorded was the most severe observed.
The diagnostic criteria for dysplasia, carcinoma in situ, and invasive carcinomas are those currently used in this laboratory and have been published ). changes, necrosis, inflammation and oedema, followed by a regenerative hyperplasia of the urothelium was evident at all dose levels of MMS and EMS. At any given dose level, the effects of MMS were more severe than those of EMS. The toxicity was dose-related and with higher doses the resulting hyperplasias although delayed, were more marked. There was some variation in the toxic response, both within individual bladders and between individual animals.
Short-term effects of MMS and EMS
In the first short-term experiment, in which MMS and EMS were administered at doses of 100mgkg-' (17.5mg per animal), toxic damage to the urothelium was visible 2 h after dosing. The intercellular spaces were dilated, some cells were vacuolated and there was focal desquamation of many superficial cells. These effects were more conspicuous at 4 h and by 1 day much of the urothelium had been stripped and some necrosis of the underlying tissues was seen. There was pronounced oedema and inflammation of the submucosa; the blood vessels, initially congested with erythrocytes, subsequently ruptured causing extensive haemorrhage. By 4 days, early focal hyperplasia of the urothelium had developed between remaining necrotic areas. Where haemorrhage had occurred into overlying urothelial tissue, erythrophagocytosis was observed as previously reported (Wakefield & Hicks, 1974) . At 7 days, some areas of the bladder were still necrotic and, although the supporting stroma had been partially restored by fibrosis, they were not yet reepithelialised. In adjacent areas, the regenerative hyperplasia of the urothelium was moderate-tomarked in nature.
In the second short-term experiment, in which the effects of lower doses of MMS and EMS were investigated, the condition of the bladder was examined at 1 and 7 days after treatment. After 50mgkg-1 MMS, the toxic damage and resultant a c urothelial hyperplasia were similar to that observed after a dose of 100mgkg-1. However, at lower doses the severity both of the damage and of the subsequent regenerative hyperplasia was reduced. One day after 20mgkg-' MMS and 50mgkg-1 EMS, there was a loss of superficial and intermediate cells leaving predominantly 1 cell thick urothelium. In small focal areas, there was complete stripping of the urothelium with necrosis of the underlying stroma, but by 7 days, the urothelium was hyperplastic to a moderate or marked degree.
After 15mgkg-1 MMS, and 20 or 35mgkg-1 EMS, urothelial damage at 1 day was limited to loss of the superficial and some intermediate cells. Complete stripping was rare and if present was confined to small localised areas. At 7 days, the urothelial hyperplasia varied in severity from mild and diffuse after the EMS (Figure 2a In the short-term studies, gross haematuria was observed 1 day after treatment with doses of 50mgkg-1 or more MMS, and with 100mgkg-1 EMS, but did not occur in animals receiving lower doses of these compounds.
From these 3 short-term trials, it was established that 15mgkg-' MMS (2.5mg per animal) and between 35 and 50mgkg-1 EMS (6.2-8.75mg per animal) were the lowest doses that would reliably elicit moderate hyperplasia without haematuria and extensive or persistent toxic damage. Therefore, for the long-term trial in which multiple doses were to be used, fraction sizes of 2.5mg MMS and 7.5mg EMS were selected to give a comparable, relatively uniform hyperplastic response.
Long-term trial Most hyperplasias observed consisted simply of thickened urothelium in which an orderly differentiation from basal to superficial cell layers was retained. Superficial cells were usually flattened, although not necessarily differentiated, but in more severe lesions the superficial cells often appeared undifferentiated. Blood vessels were often conspicuous at the base of the urothelium, occasionally infiltrating into it, particularly in the more severe hyperplasias (see Figure 4) . With one exception, nodular and papillary urothelial hyperplasias were only observed in bladders where carcinoma was also detected.
The total incidence of urothelial hyperplasia in animals killed at 2 years was dose-related, both for MMS and EMS ( Figure 3 and Table I ). The fraction sizes selected, namely 2.5 mg MMS and 7.5mg EMS, produced a remarkably comparable response in the urothelium, as predicted from the (Figures 5-7) .
In one MMS-treated animal, the bladder was lined by a grossly hyperplastic urothelium with a papillary/nodular (P/N) growth pattern. (Figure 8 ). The urothelium was well differentiated with relatively few areas of dysplasia (Figure 9 ), and although this was a borderline case, we classified it as a hyperplastic, rather than a neoplastic lesion. This bladder also contained a small free-lying calculus.
Three urothelial carcinomas developed in MMStreated animals, but none in animals treated with EMS. Two were isolated, large exophytic, welldifferentiated transitional-cell carcinomas of the bladder with invasion of the papillary stalk (Pla) (Figure 10 ). In one of these tumour-bearing bladders there was a small area of squamous metaplasia at some distance from the tumour (Figure 11 ) and also a small free-lying calculus. The third neoplasm was a carcinoma in situ in a ureter proximal to the uretero-vesical junction. In this lesion, the urothelium showed papillary hyperplasia with focal areas of obvious nuclear pleomorphism and disturbance of cellular polarity ( Figure 12) ; mitotic figures were prominent (Figure 13 ). There was diffuse papillary hyperplasia of the bladder urothelium in the same animal, but no sign of urolithiasis.
Discussion
The short-term effects described here of instilling either MMS or EMS into the bladder, confirm and Figures 4-7 Hyperplastic urothelium with blood vessel infiltration from a rat killed 2 years after a single dose of 7.5mg EMS. (Figure 4) . Features of mild urothelial dysplasia; irregular nuclear profiles (arrows, Figure 5 ), multinucleate cells (arrows, Figure 6 ) and disorientated nuclei of variable size (arrows, Figure 7 ). extend the preliminary observations of toxic damage followed by urothelial hyperplasia reported previously (Wakefield & Hicks, 1974 ). The present study shows the severity and time-course of the response to both agents to be dose related. The effects of MMS were consistently more severe than those of EMS, and in order to elicit the same degree of moderate hyperplasia with minimal toxic damage, a three-fold dose of EMS was required by comparison with MMS (i.e. 7.5mg and 2.5mg respectively). These findings are in accord with the toxic effects produced by systemic administration of EMS and MMS (LDSO values of 434mgkg-1 and 180 mg kg'-respectively (Frei, 1971 ) (see footnote a). In mutagenicity tests also, alkylating agents which react chemically via an SN2 mechanism are more cytotoxic than those reacting via an SN1 hyperplastic urothelium from the same bladder as in mechanism (see footnote b) (Pegg, 1977) . MMS is a typical SN2 type agent, whereas EMS shows both SNI and SN2 characteristics (Lawley, 1976) . The cytotoxic and hyperplastic effects of these compounds instilled directly into the bladder thus reflect their direct chemical reactivity.
For the long-term experiments, doses of MMS and EMS were selected which gave a virtually identical dose-response pattern in terms of the total numbers of proliferative lesions produced. In addition to its strong hyperplastic activity MMS, but not EMS, was weakly carcinogenic for the urothelium. Topical exposure of the bladder to bFor SNI reagents the rate-limiting step is ionisation to a carbonium ion which, being extremely electrophilic, can bind with all nucleophilic centres in the DNA. SN2 reagents do not form an intermediate carbonium ion and the transition complex formed has a relatively low electrophilic reactivity. They therefore tend to react more exclusively at the major nucleophilic centre in DNA, i.e. N7 of guanine.
aThe LD50 value of 880mg kg-1 for EMS given in Frei, 1971 , was a printer's error. (Personal communication from author). MNU leads to formation of both 7-methylguanine and 06-methylguanine in urothelial DNA, but since the enzymatic excision of 06-methylguanine takes place at a slower rate than does the repair of other DNA adducts (Cox & Irving, 1977) , it is this particular adduct which persists. There is now considerable evidence to support the hypothesis of Loveless (1969) that 06-alkylation of guanine is an important cause of miscoding in DNA and hence of mutation and tumour induction (reviewed by Lawley, 1976) . In experiments where the alkylating agents were administered systemically and a range of organs were examined (e.g. brain, liver and thymus), MMS and EMS by comparison with MNU produced little alkylation at the 06 position of guanine and their major alkylation products were 7-methylguanine and 7-ethylguanine respectively (Frei & Lawley, 1976; Frei et al., 1978) . Nevertheless, both MMS and EMS are carcinogenic in a variety of organ systems, although they are far less potent than MNU (IARC, 1974) . Working on the assumption that differences in carcinogenic activity may be related to the ability of the agent to alkylate the 06 position of the guanine residue in DNA, Frei et al. (1978) , using a thymic lymphoma model, calculated that the ratio of equipotent doses of EMS and MMS by comparison with MNU would be 21 and 144 respectively. If the induction of bladder cancer by these alkylating agents depends solely on the formation of 06_ methylguanine in urothelial DNA, then the data of Frei et al. (1978) predict that, as we confirmed, of the three MNU should be the most powerful carcinogen for the urothelium. However, they also predict that EMS should be considerably more carcinogenic than MMS, which is the reverse of what we found. Considered together, these observations indicate that after topical application of these alkylating agents to the urothelium, the carcinogenic response may not depend solely on their ability to alkylate DNA, but may reflect other biological phenomena. Analysis of the proliferative response of the urothelium reveals some interesting differences in the effect of EMS and MMS on this tissue. With both compounds, the total number of proliferative lesions produced gave excellent dose-related measure of exposure (Figure 4 ). With EMS, however, none of the hyperplasias showed abnormal growth patterns or gross dysplasia and the more severe lesions were found after the lower rather than after the higher dose levels. These expanded populations of normal urothelial cells represent the response of the urothelium to the cytotoxic damage caused by EMS and the absolute thickness of the urothelium will depend on the balance between the rates of cell death and of cell regeneration. The absence of marked dysplasia, abnormal growth patterns or any other signs of possible neoplastic conversion, implies that whatever the reaction may be between topicallyapplied EMS and the urothelial target cell DNA, it is not a mutagenic event.
MMS, on the other hand, as well as inducing flat proliferative response also produced four lesions with abnormal growth patterns, either P/N hyperplasia or papillary carcinoma. Admittedly, all were well differentiated and not aggressively invasive, i.e. they were comparable to the relatively benign papillomas produced by promoters acting on skin previously initiated by exposure to a carcinogen. This raises the possibility that MMS, unlike EMS which acts as a mitogen, may have some other specific effect on the urothelial cells. The lack of a clear-cut dose-related carcinogenic response of the urothelium to MMS does not support the theory that MMS is acting as an initiating carcinogen like MNU. It is also consistent with the fact that MMS is the least effective of the three alkylating agents at inducing point mutations in bacteria (Loveless, 1969) . Rather, the results support the hypothesis that MMS may act as a promoter and in some way permit expression of damage produced by exposure to low doses of unidentified "environmental" carcinogens or of a latent cancer gene in one or more cells in the hyperplastic urothelium. It is noteworthy that MMS is considerably more powerful than EMS in inducing sister chromatid exchange and chromosomal aberrations when tested in a Chinese hamster fibroblast model system (Perry and Evans, 1975) , and that increased sister chromatid and homologous chromosome exchange has been implicated in tumour promotion (Kinsella and Radman, 1978) . Furthermore, saccharin, an effective promoter of carcinogenesis in the initiated rat bladder, also causes the development of a few urothelial tumours in otherwise normal bladders when given on its own (Hicks et al, 1978) . Saccharin is not mutagenic but, like MMS, does cause sister chromatid exchange (Albe and Sakaki, 1977; Wolff and Rodin, 1978) . If a genetic event of this sort which is not a new mutation can result in tumour formation, this is evidence per se either that the rat urothelium carries a latent oncogene, or as we have suggested elsewhere (Chowaniec and Hicks, 1979) , that most animal populations are exposed to low levels of undetected environmental initiating carcinogens.
This study of topically-applied EMS and MMS in the urinary bladder indicates that EMS is primarily a mitogen for the urothelium. By analogy with the mouse skin model (Boutwell et al., 1982) the effect of EMS on the bladder may be comparable to that of hyperplastic agents on the skin. In that system, it was demonstrated that hyperplastic agents (e.g. turpentine, ethylphenylpropiolate, etc.) are unable to cause tumour growth from initiated cells unless in addition the tissue has been "promoted". Following initiation plus promotion such agents will, however, accelerate tumour development. By contrast with EMS, in the bladder MMS besides being a mitogen also permits the development of a few tumours. The absence of a dose-related carcinogenic response to MMS is indicative that MMS is not an initiating carcinogen in this tissue and we therefore suggest that these observations more probably reflect a promoting effect of MMS on a latent oncogene or previously initiated cell.
